Is it possible they were easy items and submitted
Post# of 157825
(Total Views: 574)
Posted On: 04/10/2023 6:52:10 PM
Re: Evil Rabbit #133947
Is it possible they were easy items and submitted already? Only problem is, it could restart the clock to 30 days?
Also saw this.
“In March 2023, as part of its conveyed long-term development and value creation initiatives, the Company made efforts to pursue the continued development of a longer-acting agent. In furtherance of this initiative, the Company entered into a joint development agreement with a third-party company to develop one or more longer-acting molecules. In addition to potentially leading to a modified therapeutic that will have greater acceptance by patients, the services provided by the third party may yield extended intellectual property protection, thereby increasing the value of the Company’s patent portfolio”
Also saw this.
“In March 2023, as part of its conveyed long-term development and value creation initiatives, the Company made efforts to pursue the continued development of a longer-acting agent. In furtherance of this initiative, the Company entered into a joint development agreement with a third-party company to develop one or more longer-acting molecules. In addition to potentially leading to a modified therapeutic that will have greater acceptance by patients, the services provided by the third party may yield extended intellectual property protection, thereby increasing the value of the Company’s patent portfolio”
(4)
(0)CytoDyn Inc (CYDY) Stock Research Links
Daniel Rizzo
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™
Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )
Website: FireGateBiotech.com
Headquarters: Washington, DC
Mailing & correspondence: 1930 18th St NW Suite B2 PMB 2161, Washington DC 20009
(For official updates and correspondence — I will no longer be posting here or responding via DMs)
Contact FireGate Biotech
Principal Investigator:
FG001|FG002|FG003
https://firegatebiotech.com/2025
FG-001: Integrated Triplet Immunotherapy for Functional HIV Cure
FG-002: Triplet Immunologic Modulation in Oncology — NF-κB / IL-1Ra Axis
FG-003: Neuro-Immune Repair Triplet — Concept and Combination Framework
CCR5 Antagonists & Triplet Immunotherapy Synergy in HIV
HIV Cure Pathways — Functional-Cure Framework Overview
FG-003 Neuro-Immune Repair Triplet — IP & Combination Strategy
— Jeremiah 51:36
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™
Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )
Website: FireGateBiotech.com
Headquarters: Washington, DC
Mailing & correspondence: 1930 18th St NW Suite B2 PMB 2161, Washington DC 20009
(For official updates and correspondence — I will no longer be posting here or responding via DMs)
Contact FireGate Biotech
Principal Investigator:
FG001|FG002|FG003
https://firegatebiotech.com/2025
FG-001: Integrated Triplet Immunotherapy for Functional HIV Cure
FG-002: Triplet Immunologic Modulation in Oncology — NF-κB / IL-1Ra Axis
FG-003: Neuro-Immune Repair Triplet — Concept and Combination Framework
CCR5 Antagonists & Triplet Immunotherapy Synergy in HIV
HIV Cure Pathways — Functional-Cure Framework Overview
FG-003 Neuro-Immune Repair Triplet — IP & Combination Strategy
— Jeremiah 51:36